This treatment was initially registered for patients with paroxysmal nocturnal hemoglobinuria (PNH), where an acquired defect in the glycophosphoinositol-anchored natural complement inhibitors, CD55 and CD59 leads to complement-mediated hemolysis (100). The gene discussed is CD55; the disease is paroxysmal nocturnal hemoglobinuria.